SMN2 and proximal spinal muscular atrophy: Onasemnogene abeparvovec (OA), an adeno-associated viral vector-based gene therapy, developed to carry a functional copy of the gene encoding full-length SMN protein directly to motor neuron, was the first gene therapy approved as treatment for SMA in the United States (7).